PCRX-201 became part of Pacira's portfolio in 2021, but was originally developed at Baylor and then by GQ Bio Therapeutics, ...

Ataraxis AI will use the new funding to bring to market its first offering, Ataraxis Breast, an AI-native prognostic/predictive platform for breast cancer.

Researchers are testing whether the Clarity ctDNA test can reliably identify patients who do just as well long term with less chemotherapy.

Troculeucel is an immunotherapeutic, in which a patient's autologous natural killer cells are expanded ex vivo. It is designed to reduce or prevent chronic neuroinflammation in patients who have ...

The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.

In the randomized, sham-controlled ARTEMIS study, patients will receive either a dose of ixo-vec or a standard care regimen of anti-VEGF Eylea.

Patients with PD-L1-positive tumors lived more than seven months longer on Tevimbra added to chemotherapy compared to just chemo.

ABI-201 is undergoing IND-enabling studies and uses the same capsid as the firm's clinical-stage gene therapy candidate for wet AMD.

In a recent trial, researchers found that Xpovio plus chemo had activity in NSCLC patients with KRAS mutations other than ...

The firm said its remaining employees will focus on developing the pol theta inhibitor RP-3467 and the PLK4 inhibitor RP-1664.

The company said the move demonstrates the board of directors' confidence in the potential of its PARP1/2 inhibitor in ovarian cancer.

The European Commission had requested the committee consider new data on the drug that became available after it had adopted its positive opinion.